210 related articles for article (PubMed ID: 30315115)
1. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity.
Fujiwara Y; Sun Y; Torphy RJ; He J; Yanaga K; Edil BH; Schulick RD; Zhu Y
Cancer Res; 2018 Dec; 78(23):6655-6665. PubMed ID: 30315115
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
3. An Immunomodulatory Gallotanin-Rich Fraction From
Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
Front Immunol; 2020; 11():584959. PubMed ID: 33312174
[TBL] [Abstract][Full Text] [Related]
4. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
[TBL] [Abstract][Full Text] [Related]
5. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.
Ke M; Zhang Z; Xu B; Zhao S; Ding Y; Wu X; Wu R; Lv Y; Dong J
Int Immunopharmacol; 2019 Oct; 75():105824. PubMed ID: 31437792
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
7. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
Jiang C; Yuan F; Wang J; Wu L
Immunobiology; 2017 Apr; 222(4):651-657. PubMed ID: 28017495
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors.
Shi S; Gu S; Han T; Zhang W; Huang L; Li Z; Pan D; Fu J; Ge J; Brown M; Zhang P; Jiang P; Wucherpfennig KW; Liu XS
Clin Cancer Res; 2020 Nov; 26(22):5990-6002. PubMed ID: 32723834
[TBL] [Abstract][Full Text] [Related]
10. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
11. Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth.
Rawangkan A; Wongsirisin P; Namiki K; Iida K; Kobayashi Y; Shimizu Y; Fujiki H; Suganuma M
Molecules; 2018 Aug; 23(8):. PubMed ID: 30126206
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma.
Young MH; Pietz G; Whalen E; Copeland W; Thompson E; Fox BA; Newhall KJ
Sci Rep; 2021 Aug; 11(1):16460. PubMed ID: 34385543
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.
Rangan L; Galaine J; Boidot R; Hamieh M; Dosset M; Francoual J; Beziaud L; Pallandre JR; Lauret Marie Joseph E; Asgarova A; Borg C; Al Saati T; Godet Y; Latouche JB; Valmary-Degano S; Adotévi O
Oncotarget; 2017 Jul; 8(30):48959-48971. PubMed ID: 28430664
[TBL] [Abstract][Full Text] [Related]
14. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
Noguchi T; Ward JP; Gubin MM; Arthur CD; Lee SH; Hundal J; Selby MJ; Graziano RF; Mardis ER; Korman AJ; Schreiber RD
Cancer Immunol Res; 2017 Feb; 5(2):106-117. PubMed ID: 28073774
[TBL] [Abstract][Full Text] [Related]
15. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Barsoum IB; Smallwood CA; Siemens DR; Graham CH
Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
[TBL] [Abstract][Full Text] [Related]
16. Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.
Li C; Yao H; Wang H; Fang JY; Xu J
Oncogene; 2021 Feb; 40(6):1128-1146. PubMed ID: 33323966
[TBL] [Abstract][Full Text] [Related]
17. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
Ballesteros-Briones MC; Martisova E; Casales E; Silva-Pilipich N; Buñuales M; Galindo J; Mancheño U; Gorraiz M; Lasarte JJ; Kochan G; Escors D; Sanchez-Paulete AR; Melero I; Prieto J; Hernandez-Alcoceba R; Hervas-Stubbs S; Smerdou C
Mol Ther; 2019 Nov; 27(11):1892-1905. PubMed ID: 31563534
[TBL] [Abstract][Full Text] [Related]
18. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Cha JH; Yang WH; Xia W; Wei Y; Chan LC; Lim SO; Li CW; Kim T; Chang SS; Lee HH; Hsu JL; Wang HL; Kuo CW; Chang WC; Hadad S; Purdie CA; McCoy AM; Cai S; Tu Y; Litton JK; Mittendorf EA; Moulder SL; Symmans WF; Thompson AM; Piwnica-Worms H; Chen CH; Khoo KH; Hung MC
Mol Cell; 2018 Aug; 71(4):606-620.e7. PubMed ID: 30118680
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Juneja VR; McGuire KA; Manguso RT; LaFleur MW; Collins N; Haining WN; Freeman GJ; Sharpe AH
J Exp Med; 2017 Apr; 214(4):895-904. PubMed ID: 28302645
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Richardson PG; Mark TM; Lacy MQ
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
